Microbio Co., Ltd. (TPEX:4128)

Taiwan · Delayed Price · Currency is TWD

15.50

+0.40 (2.65%)

Oct 16, 2026, 1:30 PM CST

Market Cap	9.12B -29.9%
Revenue (ttm)	1.97B +8.4%
Net Income	523.23M
EPS	0.89
Shares Out	588.17M
PE Ratio	17.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,353,832
Open	15.20
Previous Close	15.10
Day's Range	15.20 - 15.60
52-Week Range	13.60 - 22.80
Beta	0.49
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Microbio

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and health foods in Taiwan. It provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. The company is also involved in the sale of organic food and beverages; provision of technology development, transfer, and consulting services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd.... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 2000

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 4128

Full Company Profile

Financial Performance

In 2025, Microbio's revenue was 1.89 billion, an increase of 9.94% compared to the previous year's 1.72 billion. Losses were -757.75 million, -31.16% less than in 2024.

Financial Statements